1 Building The Future of Immune Therapeutics Company Overview March 2026 Forward Looking Statements This presentation has been prepared byQ32 Bio Inc. ("we", "us," "our," "Q32" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances cre ...

Bempikibart (ADX-914) for Alopecia Areata (AA) - Bempikibart demonstrated proof of concept in alopecia areata with favorable safety profile and robust changes in Th2 clinical biomarkers[9] - SIGNAL-AA Phase 2a Part A showed continued benefit through Week 36, supporting potential for durable effect following dosing cessation[25] - In SIGNAL-AA Part A, patients with baseline SALT 50-100 showed a mean SALT score percentage change of 163% at Week 24 and 199% at Week 36[29] - In SIGNAL-AA Part A, patients with baseline SALT 50-95 showed a mean SALT score percentage change of 245% at Week 24 and 278% at Week 36[29] - The company anticipates Bempikibart SIGNAL-AA Phase 2a Part B topline results in the first half of 2026[10, 71] - The company has received FDA Fast Track designation for Bempikibart for the treatment of AA[11] Alopecia Areata Market and Unmet Need - There are approximately 700,000 AA patients in the US[9, 45, 49] - The expected market size for AA is $26 billion by 2030[9] - Approximately 300,000 US Alopecia Areata (AA) Patients have Severe (SALT > 50)[49] - Currently available therapies for AA lack the desired profile, and doctors and patients seek alternatives to currently approved agents including JAK inhibitors which carry significant safety risks[9, 45, 46] ADX-097 and Complement Platform - ADX-097 is Phase 2 ready and the company is evaluating strategic next steps for ADX-097 and the complement inhibitor platform[11] - ADX-097 Phase 1 study achieved primary goals, demonstrating dose-dependent PK/PD and a favorable safety profile[62] Financial Overview - The company's Q2 2025 cash balance was $548 million, providing expected cash runway into 2027[71]